Evidence-Based Treatment for a Newly Diagnosed Open-Angle Glaucoma Patient_Chinese Journal of Evidence-Based Medicine

Authors：

QIAN ZhiGang ,  KE Min , GUO Jing , HU Xinqian

The Department of Zhongnan Hospital of Wuhai University, Wuhan 430071, China;

Corresponding author：

KE Min, Email: keminyk@163.com

Keywords：

Open-angle glaucoma; Timolol; Ltanoprost; Trabeculectomy; Evidence-based treatment

DOI：

10.7507/1672-2531.20100554

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　Methods of evidence-based medicine were used to make an individualized treatment plan concerning newly diagnosed open-angle glaucoma patient.
Methods 　After clinical problems were put forward, evidence was collected from Cochrane Library (Issue 4, 2009), PubMed (1990 -2009), MEDLINE (1990-2009), EMbase (1990-2009), CBM (1990-2009), and CNKI (1990-2009) according to the search strategy. Subject words were open-angle glaucoma, timolol, latanoprost, trabeculectomy, intraocular pressure, randomized controlled trials, human, meta-analysis, systematic review.
Results　 A total of 221 randomized controlled trials, and 19 systematic reviews were identified. A rational treatment plan was made upon a serious evaluation of the data. After one year follow-up, the plan was proved optimal.
Conclusion 　The treatment efficacy in newly diagnosed open-angle glaucoma has been improved by determining an individualized treatment plan according to evidence-based methods.

Citation： QIAN ZhiGang,KE Min,GUO Jing,HU Xinqian. Evidence-Based Treatment for a Newly Diagnosed Open-Angle Glaucoma Patient. Chinese Journal of Evidence-Based Medicine, 2010, 10(9): 1120-1124. doi: 10.7507/1672-2531.20100554 Copy

1.	Palmberg P, Traget IOP. How low? American Academy of Ophthalmology Subspecialty Day glaucoma meeting; 2001Nov 10; New Orleans.
2.	Tuulonen A, Airaksinen PJ. The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol. Scand, 2003, 81: 3-18.
3.	Collaborative Normal-tension Glaucoma Study Group (CNTGS). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol, 1998, 126(4): 498-505.
4.	Capr iol IJ, Fasterland DE, Gross RL, et al. Preferred practice pattern for primary open-angle glaucoma. San Francisco: American Academy of Ophthalmology, 2002: 1-2.
5.	The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma.Ophthalmology. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, Mills RP; CIGTS Study Group. 2001 Nov; 108(11): 1954-1965.
6.	Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Op in Pharmacother, 2007, 8(18): 3237-3249.
7.	Mundorf TK, Ogawa T, Naka H, et al. US Istalol Study Group.A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther, 2004, 26(4): 541-51.
8.	Husan S, Crosson CE. Role of PK cepsilon in PGF-alpha2 stimulated MMP-2 secretion from human ciliary muscle cells. J Ocul Pharmacol Ther, 2008, 24(3): 268-277.
9.	Ishda N, Odan I-Kawabata N, Sh imazaki A, et al. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev, 2006, 24 (1): 1-10.
10.	张铭志, 傅智伏, 刘晓瑞, 等. 原发性开角型青光眼与正常人群搏动性眼血流量比较研究. 中华眼科杂志, 2004 , 40: 250-253.
11.	Lim KS, Nau CB, Megan M, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in health subjects. A cross-over study. Ophthalmology, 2008, 115(5): 790-795.
12.	Cunl IFFE I. New drugs in glaucoma therapy. Hospital Medicine, 2003, 64(3): 156-160.
13.	Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol, 2001, 131(1): 19-24.
14.	Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Op in Ophthalmol, 2005, 16(2): 79-83.
15.	Ishii K, Tomidokoro A, Nagahara M, et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkey,and humans. Invest Ophthalmol Vis Sci, 2001, 42 (12): 2957-2963.
16.	Alm A, Stjernschantz J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol, 1995, 79(1): 12-16.
17.	Camras CB, the United States latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States.Ophthalmology, 1996, 103: 138-147.
18.	Watson P, Stjernschantz J, the latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension.Ophthalmology, 1996, 103: 126-137.
19.	Fristr?m B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol Scand, 1996, 74(2): 140-144.
20.	Perry CM, McGavin JK. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging, 2003, 20(8): 597-630.
21.	彭大伟, 李绍珍, 等. latanoprost 与噻吗心安治疗开角型青光眼及高眼压症的临床对照研究. 中华眼科杂志, 2000, 36(4): 285-288.
22.	Hitchings RA. Primary surgery for primary open angle glaucoma--justified or not? Br J Ophthalmol, 1993, 77: 445-448.
23.	Jay JL. Rational choice of therapy in primary open angle glaucoma. Eye(Lond), 1992, 6: 243-247.
24.	叶天才, 张秀兰, 等. 非穿透性小梁手术联合透明质酸植入物治疗开角型青光眼. 中华眼科杂志, 2001, 37(4): 273-277.
25.	Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev, 2005, 18(2).
26.	Webers CA, van der Valk R, Schouten JS, et al. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology, 2007, 114(1): 40-46.
27.	Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother, 2008, 42(4): 498-504.
28.	Hodgew G, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patient compared to dorzolaminde and brimonidine: a systematic review. Br J Ophthalmol, 2008, 92(1): 7-12.
29.	梅丽克木?艾山, 具尔提?哈德尔. 多佐胺和噻吗洛尔联用与拉坦前列腺素比较治疗开角型青光眼的系统评价. 中国循证医学杂志, 2009, 9(3): 350-354.

1. Palmberg P, Traget IOP. How low? American Academy of Ophthalmology Subspecialty Day glaucoma meeting; 2001Nov 10; New Orleans.
2. Tuulonen A, Airaksinen PJ. The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol. Scand, 2003, 81: 3-18.
3. Collaborative Normal-tension Glaucoma Study Group (CNTGS). The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol, 1998, 126(4): 498-505.
4. Capr iol IJ, Fasterland DE, Gross RL, et al. Preferred practice pattern for primary open-angle glaucoma. San Francisco: American Academy of Ophthalmology, 2002: 1-2.
5. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma.Ophthalmology. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, Mills RP; CIGTS Study Group. 2001 Nov; 108(11): 1954-1965.
6. Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Op in Pharmacother, 2007, 8(18): 3237-3249.
7. Mundorf TK, Ogawa T, Naka H, et al. US Istalol Study Group.A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther, 2004, 26(4): 541-51.
8. Husan S, Crosson CE. Role of PK cepsilon in PGF-alpha2 stimulated MMP-2 secretion from human ciliary muscle cells. J Ocul Pharmacol Ther, 2008, 24(3): 268-277.
9. Ishda N, Odan I-Kawabata N, Sh imazaki A, et al. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev, 2006, 24 (1): 1-10.
10. 张铭志, 傅智伏, 刘晓瑞, 等. 原发性开角型青光眼与正常人群搏动性眼血流量比较研究. 中华眼科杂志, 2004 , 40: 250-253.
11. Lim KS, Nau CB, Megan M, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in health subjects. A cross-over study. Ophthalmology, 2008, 115(5): 790-795.
12. Cunl IFFE I. New drugs in glaucoma therapy. Hospital Medicine, 2003, 64(3): 156-160.
13. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol, 2001, 131(1): 19-24.
14. Grieshaber MC, Flammer J. Blood flow in glaucoma. Curr Op in Ophthalmol, 2005, 16(2): 79-83.
15. Ishii K, Tomidokoro A, Nagahara M, et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkey,and humans. Invest Ophthalmol Vis Sci, 2001, 42 (12): 2957-2963.
16. Alm A, Stjernschantz J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol, 1995, 79(1): 12-16.
17. Camras CB, the United States latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States.Ophthalmology, 1996, 103: 138-147.
18. Watson P, Stjernschantz J, the latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension.Ophthalmology, 1996, 103: 126-137.
19. Fristr?m B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol Scand, 1996, 74(2): 140-144.
20. Perry CM, McGavin JK. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging, 2003, 20(8): 597-630.
21. 彭大伟, 李绍珍, 等. latanoprost 与噻吗心安治疗开角型青光眼及高眼压症的临床对照研究. 中华眼科杂志, 2000, 36(4): 285-288.
22. Hitchings RA. Primary surgery for primary open angle glaucoma--justified or not? Br J Ophthalmol, 1993, 77: 445-448.
23. Jay JL. Rational choice of therapy in primary open angle glaucoma. Eye(Lond), 1992, 6: 243-247.
24. 叶天才, 张秀兰, 等. 非穿透性小梁手术联合透明质酸植入物治疗开角型青光眼. 中华眼科杂志, 2001, 37(4): 273-277.
25. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev, 2005, 18(2).
26. Webers CA, van der Valk R, Schouten JS, et al. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology, 2007, 114(1): 40-46.
27. Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother, 2008, 42(4): 498-504.
28. Hodgew G, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patient compared to dorzolaminde and brimonidine: a systematic review. Br J Ophthalmol, 2008, 92(1): 7-12.
29. 梅丽克木?艾山, 具尔提?哈德尔. 多佐胺和噻吗洛尔联用与拉坦前列腺素比较治疗开角型青光眼的系统评价. 中国循证医学杂志, 2009, 9(3): 350-354.

Previous Article
Clinical Analysis on 138 Cases of Removing Esophageal Foreign Bodies in Children by Utilizing Foley Catheter
Next Article
Clinical Evidence of the Hormone Replacement Therapy for Osteoporosis

Chinese Journal of Evidence-Based Medicine

Evidence-Based Treatment for a Newly Diagnosed Open-Angle Glaucoma Patient

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content